Vaccine maker Adimmune Corp (國光生技) yesterday said that it began the phase 1 trial of its COVID-19 vaccine this week.
The firm did not say when the first of an expected 70 participants was vaccinated and if there were any side effects.
It would reveal more information later, Adimmune said.
“Given that the novel coronavirus is mysterious, with some patients reportedly reinfected after being discharged, we would closely watch whether our candidate vaccine could induce an effective antibody against the virus and how long the antibody can remain protective,” Adimmune president Liu Chung-cheng (留忠正) told a media briefing in Taipei.
The company expects to enroll 70 volunteers by the middle of October with the help of National Taiwan University Hospital (NTUH), Liu said.
“Enrolling would take some time, as we are seeking volunteers who do not have chronic diseases, which is so determining a cause is not too difficult if side effects arise,” Adimmune spokesman Pan Fei (潘飛) said.
Adimmune, which previously planned to divide the 70 participants into three groups who would receive low, medium or high doses, would add one more group of participants to receive low doses combined with an adjuvant, which can boost the immune response of a vaccine, Pan said.
The plan is to apply to begin a phase 2 trial in early December, in which the candidate vaccine would be administered to 3,000 participants, Pan said.
The second-phase trial would include participants with other health issues to test the vaccine’s effect on such people, he said.
“Our goal is to enroll at least 1,500 participants for the phase 2 clinical trial, but the more the merrier,” Adimmune chairman Steve Chan (詹啟賢) said.
The company expects to end the phase 2 trial by Lunar New Year next year, which is in the middle of February, but it would continue monitoring participants for at least a year, Chan said.
As several companies and regulators in countries such as Brazil, Turkey, the Czech Republic, Singapore, Vietnam and the Philippines have expressed interest in cooperating with Adimmune on development of the vaccine, the firm would consider a multicenter, multinational phase 3 trial, Chan said.
Separately, TaiMed Biologics Inc (中裕新藥) on Tuesday signed a deal with Columbia University to gain access to a COVID-19 antibody developed by Aaron Diamond AIDS Research Center science director David Ho (何大一), a professor of medicine at the New York university who directed the work on the antibody, the firm said in a filing with the Taiwan Stock Exchange yesterday.
The antibody, among the nine that Ho’s team isolated from several patients severely infected with COVID-19, is expected to be a potent neutralizer of the novel coronavirus, TaiMed Biologics said.
The company would apply to the US Food and Drug Administration to conduct a phase 1 human test of the antibody in the spring of next year, TaiMed Biologics said.
It did not reveal the amount it paid to the university.
The rise of the cryptocurrency dogecoin has reached a new level after the token was used to pay for a lunar satellite launch. SpaceX, Elon Musk’s commercial rocket firm, is to embark on a moon voyage next year carrying a so-called cubesat — a mini-satellite used for space research — from Geometric Energy Corp that has been paid for entirely in dogecoin. The development is the latest twist in the saga over the digital token, which started as a joke in 2013, but is now a dominating Internet meme and sitting on a 21,000 percent rally in the past year. Musk has
The Financial Supervisory Commission (FSC) yesterday fined Citibank Taiwan Ltd (花旗台灣) NT$10 million (US$357,194) and DBS Bank Taiwan (星展台灣) NT$6 million for breaches of the nation’s anti-money laundering (AML) regulations. The NT$10 million fine is the highest penalty that it has imposed on a domestic bank, the commission said. Citibank Taiwan failed to set up a sound mechanism for evaluating clients’ risk of money laundering and for detecting suspicious transactions, Banking Bureau Deputy Director-General Huang Kuang-hsi (黃光熙) told a news conference in New Taipei City. The bank based its AML policies on those of its US-based parent company, Citigroup Inc, but the policies
CAPACITY EXPANSION: Construction of the site, which is to be the firm’s first mRNA production facility outside of Europe, is to begin this year and likely finish in 2023 COVID-19 vaccine maker BioNTech SE yesterday said it would build a Southeast Asia headquarters and manufacturing site in Singapore to produce hundreds of millions of messenger RNA (mRNA)-based vaccines per year. Construction of the site would start this year, and it could become operational by 2023, the German company said in a statement. “With this planned mRNA production facility, we will increase our overall network capacity, and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world,” BioNTech chief executive Ugur Sahin said. The vaccine produced by BioNTech jointly with Pfizer Inc of
OUTBREAK: About 200 of the airline’s 1,200 pilots are not able to work. Most of them have been quarantined to prevent further infection, but 12 have COVID-19 China Airlines Ltd (CAL,中華航空) yesterday confirmed that it would temporarily reduce its cargo flight services to cope with a pilot shortage, as one-sixth of its pilots have been sidelined by a COVID-19 outbreak. “We are working out a new schedule,” the airline said in a statement after local news media reports on Saturday said that it would be reducing its cargo services from Wednesday, primarily affecting US destinations. CAL declined to give details about its new operating plan, but the reports said that it would be suspending its cargo flights to Dallas Fort Worth International Airport, Hartsfield-Jackson Atlanta International Airport and